2007 · FINDING
CITEDFalutz et al. — Pivotal VAT reduction
N=412, 26-week RCT: 15.2% VAT reduction vs. placebo in HIV patients with lipodystrophy. Basis for FDA approval.
⚕ EDUCATIONAL CONTENT · NOT MEDICAL ADVICE · CONSULT A QUALIFIED PHYSICIAN BEFORE ANY USE
MUSCLE & RECOVERYFDA APPROVED
Tesamorelin.
FDA-approved GHRH analog with clean GH/IGF-1 elevation
AKA · Egrifta · TH9507
MUSCLE & RECOVERYLONGEVITYSUBCUTANEOUS
A stable 44-residue GHRH analog. FDA-approved for HIV-associated lipodystrophy; extensively studied off-label for visceral fat reduction in healthy adults. The only GHRH with meaningful human data at scale.
~40 minutes (extended receptor effect)
Half-life
3
Citations
1
Routes
2
Categories
Refrigerate
Storage
82
Popularity
AT A GLANCE.
§ 01 · TL;DRTHE QUICK READ.
A stable 44-residue GHRH analog. FDA-approved for HIV-associated lipodystrophy; extensively studied off-label for visceral fat reduction in healthy adults. The only GHRH with meaningful human data at scale.
Tells your pituitary to release growth hormone naturally. The GH elevation is pulsatile and physiological — not a GH replacement.
Rotate injection sites. Minimum 12-week cycle to see body composition changes.
WHAT IT MIGHT HELP WITH.
1
15–18% reduction in visceral adipose tissue over 26 weeks
2
IGF-1 elevation into healthy young-adult range
3
Improved body composition (lean mass retention)
4
Improved lipid profile — lower triglycerides
5
No known tachyphylaxis (effect persists with continued dosing)
HOW IT WORKS.
§ 02 · MECHANISMTells your pituitary to release growth hormone naturally. The GH elevation is pulsatile and physiological — not a GH replacement.
Stabilized GHRH(1-44)NH2 with an N-terminal trans-3-hexenoic acid modification that resists DPP-4 degradation. Binds GHRH receptors on pituitary somatotrophs, increases IGF-1 5-fold, preferentially reduces visceral adipose tissue (VAT) by ~15–18% in trials.
WHO IT'S FOR
- ✓Adults with abdominal visceral fat
- ✓Those seeking lean-preserving fat loss
- ✓Researchers tracking IGF-1 responses
WHO SHOULD AVOID
- ✕Active malignancy
- ✕Pregnancy / breastfeeding
- ✕Uncontrolled diabetes
- ✕Acute critical illness
THE RESEARCH.
§ 03 · 3 STUDIES2014 · FINDING
CITEDStanley et al. — MASH/NAFLD
Reduced hepatic fat fraction by 37% over 6 months in HIV patients with NAFLD.
2017 · FINDING
Clemmons review — body composition
Review of 5 trials: consistent ~15–18% VAT reduction, IGF-1 ~150 ng/mL baseline increase.
DOSING PROTOCOL.
§ 04 · DOSINGTYPICAL RANGE
Rotate injection sites. Minimum 12-week cycle to see body composition changes.
2mg subcutaneous daily
FREQUENCY
Most-cited schedule
Once daily (bedtime most common)
ROUTES
Delivery methods
SUBCUTANEOUS
HALF-LIFE
Steady state drives frequency
~40 minutes (extended receptor effect)
STORAGE
Protect from light, refrigerate
Refrigerate 2–8°C before
⚠ NOTE
These are reported protocols from research literature and practitioner accounts, not prescriptions. No FDA-approved human dose exists for research compounds. Anyone using Tesamorelin should work with a qualified physician and source from a supplier providing third-party COAs.
FORMS AVAILABLE
- · Lyophilized vial, 2mg or 10mg
⚠ RESEARCH INFORMATION ONLY · NOT MEDICAL ADVICE
COMMON STACKS.
§ 05 · COMBINATIONSSIDE EFFECTS & RISKS.
§ 06 · SAFETY·
Injection site reactions
Common (15%) · mild
·
Joint pain / stiffness
Common (10%) · mild
Related to IGF-1 elevation — typically resolves
·
Peripheral edema
Occasional · mild
•
Hyperglycemia
Monitored · moderate
Check fasting glucose if diabetic or pre-diabetic
WHERE TO SOURCE
§ 07 · SUPPLIERPEAK LAB
PEPTIDES
PEPTIDES
SUPPLIER OF RECORD · 12 BATCHES PASSED
We tried nine suppliers across 2025 and kept picking PEAK LAB for Tesamorelin: 99.4% HPLC purity, COA on every batch, cold chain intact. Shop through our link and we earn a small commission — affiliate relationship is disclosed.
◆ THE PEPGAINS DISPATCH
GET THE NEXT UPDATE FIRST.
New research on Tesamorelin + a weekly dispatch on everything else moving in the peptide world. One email. Unsubscribe in a click.